Patents by Inventor Masaki Otagiri

Masaki Otagiri has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10328710
    Abstract: A recording apparatus includes a recording head, an ink supply section, a carriage, and a detection unit. The ink supply section supplies ink to the recording head. The carriage reciprocates in predetermined directions and is provided with the recording head and includes a passage junction to be connected to or disconnected from an ink passage formed between the ink supply section and the recording head. The detection unit converts a result of detecting a detection target into an electrical signal. One of the detection target and the detection unit is mounted in the carriage. The carriage has an ink guiding mechanism that guides the ink from a region positioned below the passage junction in a vertical direction to the detection target or an installation part for the detection unit.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: June 25, 2019
    Assignee: Seiko Epson Corporation
    Inventors: Masaki Shimomura, Yoshihiro Otagiri
  • Patent number: 9744217
    Abstract: The purpose of the present invention is to establish a novel therapy method for hyperbilirubinemia and therefore, to provide a bilirubin excretion enhancer. The present invention provides a bilirubin excretion enhancer comprising, as an active ingredient, a serum albumin domain II-like protein comprising a serum albumin subdomain IIA. In one embodiment, the serum albumin subdomain IIA has an amino acid sequence of SEQ ID NO: 1. in one embodiment, the serum albumin domain II-like protein is a serum albumin domain II. In one embodiment, the serum albumin domain II comprises the amino acid sequence of SEQ ID NO: 4.
    Type: Grant
    Filed: October 7, 2015
    Date of Patent: August 29, 2017
    Assignee: Nipro Corporation
    Inventors: Masaki Otagiri, Toru Maruyama, Yu Ishima, Ai Minomo
  • Publication number: 20160058844
    Abstract: The purpose of the present invention is to establish a novel therapy method for hyperbilirubinemia and therefore, to provide a bilirubin excretion enhancer. The present invention provides a bilirubin excretion enhancer comprising, as an active ingredient, a serum albumin domain II-like protein comprising a serum albumin subdomain IIA. In one embodiment, the serum albumin subdomain IIA has an amino acid sequence of SEQ ID NO: 1. in one embodiment, the serum albumin domain II-like protein is a serum albumin domain II. In one embodiment, the serum albumin domain II comprises the amino acid sequence of SEQ ID NO: 4.
    Type: Application
    Filed: October 7, 2015
    Publication date: March 3, 2016
    Inventors: Masaki Otagiri, Toru Maruyama, Yu Ishima, Ai Minomo
  • Publication number: 20140187744
    Abstract: The purpose of the present invention is to establish a novel therapy method for hyperbilirubinemia and therefore, to provide a bilirubin excretion enhancer. The present invention provides a bilirubin excretion enhancer comprising, as an active ingredient, a serum albumin domain II-like protein comprising a serum albumin subdomain IIA. In one embodiment, the serum albumin subdomain IIA has an amino acid sequence of SEQ ID NO: 1. In one embodiment, the serum albumin domain II-like protein is a serum albumin domain II. In one embodiment, the serum albumin domain II comprises the amino add sequence of SEQ ID NO: 4.
    Type: Application
    Filed: August 9, 2012
    Publication date: July 3, 2014
    Applicant: NIPRO CORPORATION
    Inventors: Masaki Otagiri, Toru Maruyama, Yu Ishima, Ai Minomo
  • Patent number: 7943570
    Abstract: Glycosylated albumin as a drug carrier for a DDS targeting the liver (particularly kupffer's cell) can be provided by mutating a DNA encoding albumin to encode a mutant albumin containing a partial amino acid sequence permitting glycosylation modification by eukaryotic cell, preferably a consensus sequence of N-linked sugar chain, introducing an expression vector containing the mutant DNA into a host eukaryotic cell, preferably a host cell permitting addition of a high-mannose type sugar chain, culturing the obtained transformant, and recovering a glycosylated albumin protein from the obtained culture.
    Type: Grant
    Filed: October 16, 2007
    Date of Patent: May 17, 2011
    Assignee: Nipro Corporation
    Inventors: Keisuke Nakajou, Naohisa Katayama, Toshiya Kai, Masaki Otagiri
  • Patent number: 7893212
    Abstract: The present invention provides an S-nitroso group-containing albumin, comprising an S-nitroso group introduced to at least one lysine in the amino acid sequence for albumin. The S-nitro group has been introduced into a lysine in the S-nitroso group-containing albumin of the invention to allow more S-nitroso groups to be included in the albumin, thus ensuring more potent inhibition of cancer cells in NO groups.
    Type: Grant
    Filed: August 29, 2008
    Date of Patent: February 22, 2011
    Assignee: Nipro Corporation
    Inventors: Masaki Otagiri, Keisuke Nakajo, Naohisa Katayama, Toshiya Kai
  • Patent number: 7803759
    Abstract: A protein is efficiently nitrosylated with nitrogen monoxide by merely mixing S-nitrosoglutathione as a nitrogen monoxide donor with a protein solution containing a stabilizing agent comprising at least one compound or a combination of plural compounds selected from an N-acetylamino acid, a fatty acid, and a fatty acid salt. The method that enables efficient NO addition to a cysteine residue in un-nitrosylated protein without changing the structure of protein and hence provides NO to a living organism.
    Type: Grant
    Filed: August 7, 2007
    Date of Patent: September 28, 2010
    Assignee: Nipro Corporaton
    Inventors: Yu Ishima, Takaaki Akaike, Masaki Otagiri
  • Patent number: 7718607
    Abstract: A protein is efficiently nitrosylated with nitrogen monoxide by merely mixing S-nitrosoglutathione as a nitrogen monoxide donor with a protein solution containing a stabilizing agent comprising at least one compound or a combination of plural compounds selected from an N-acetylamino acid, a fatty acid, and a fatty acid salt. The method that enables efficient NO addition to a cysteine residue in un-nitrosylated protein without changing the structure of protein and hence provides NO to a living organism.
    Type: Grant
    Filed: July 11, 2008
    Date of Patent: May 18, 2010
    Assignee: NIPRO Corporation
    Inventors: Yu Ishima, Takaaki Akaike, Masaki Otagiri
  • Publication number: 20090099071
    Abstract: Glycosylated albumin as a drug carrier for a DDS targeting the liver (particularly kupffer's cell) can be provided by mutating a DNA encoding albumin to encode a mutant albumin containing a partial amino acid sequence permitting glycosylation modification by eukaryotic cell, preferably a consensus sequence of N-linked sugar chain, introducing an expression vector containing the mutant DNA into a host eukaryotic cell, preferably a host cell permitting addition of a high-mannose type sugar chain, culturing the obtained transformant, and recovering a glycosylated albumin protein from the obtained culture.
    Type: Application
    Filed: October 16, 2007
    Publication date: April 16, 2009
    Applicant: NIPRO CORPORATION
    Inventors: Keisuke NAKAJOU, Naohisa KATAYAMA, Toshiya KAI, Masaki OTAGIRI
  • Publication number: 20090098630
    Abstract: Fusion protein comprises a thioredoxin and human serum albumin. The thioredoxin comprises a protein comprising the amino acid sequence shown in SEQ. ID. No. 1, or the like, the human serum albumin comprises a protein comprising the amino acid sequence shown in SEQ. ID. No. 2, or the like. The fusion protein of the invention allows the activity of thioredoxin to be maintained over a long period of time. It is thus possible to provide a protein preparation that is stable over long periods of time.
    Type: Application
    Filed: August 29, 2008
    Publication date: April 16, 2009
    Applicant: NIPRO CORPORATION
    Inventors: Masaki OTAGIRI, Shotaro Ikuta
  • Publication number: 20090099337
    Abstract: The present invention provides an S-nitroso group-containing albumin, comprising an S-nitroso group introduced to at least one lysine in the amino acid sequence for albumin. The S-nitro group has been introduced into a lysine in the S-nitroso group-containing albumin of the invention to allow more S-nitroso groups to be included in the albumin, thus ensuring more potent inhibition of cancer cells in NO groups.
    Type: Application
    Filed: August 29, 2008
    Publication date: April 16, 2009
    Applicant: NIPRO CORPORATION
    Inventors: Masaki Otagiri, Keisuke Nakajo, Naohisa Katayama, Toshiya Kai
  • Publication number: 20090098607
    Abstract: The present invention provides a production method of a functional recombinant human hemoglobin, which comprises transforming a yeast of the genus Pichia with an expression vector containing a DNA encoding a human hemoglobin ?-chain (Hb?), which is under regulation of a promoter functional in a yeast of the genus Pichia, and an expression vector containing a DNA encoding a human hemoglobin ?-chain (Hb?), which is under regulation of a promoter functional in a yeast of the genus Pichia, culturing the yeast in a medium, and recovering the human hemoglobin from the obtained culture. The present invention also provides an expression vector containing AOX1 promoter, DNA encoding Hb?, terminator functional in a yeast of the genus Pichia, AOX1 promoter, DNA encoding Hb? and terminator functional in the yeast of the genus Pichia in this order from the upstream side in transcriptional direction.
    Type: Application
    Filed: October 16, 2007
    Publication date: April 16, 2009
    Applicant: NIPRO CORPORATION
    Inventors: Keisuke NAKAJOU, Yohei HOASHI, Toshiya KAI, Tadayuki UNO, Masaki OTAGIRI
  • Publication number: 20080287655
    Abstract: A protein is efficiently nitrosylated with nitrogen monoxide by merely mixing S-nitrosoglutathione as a nitrogen monoxide donor with a protein solution containing a stabilizing agent comprising at least one compound or a combination of plural compounds selected from an N-acetylamino acid, a fatty acid, and a fatty acid salt. The method that enables efficient NO addition to a cysteine residue in un-nitrosylated protein without changing the structure of protein and hence provides NO to a living organism.
    Type: Application
    Filed: July 11, 2008
    Publication date: November 20, 2008
    Inventors: Yu Ishima, Takaaki Akaike, Masaki Otagiri
  • Patent number: 7351800
    Abstract: This invention provides albumin preparations with safety and without any risk of side effects, which are free from viruses or contaminating proteins and can be stably stored over a long time while showing neither changes in appearance nor decrease in content. There are provided a stabilized albumin preparation produced by uniformly mixing a medium-chain fatty acid or a salt thereof and a sulfur-containing amino acid or a derivative thereof with an aqueous albumin solution (e.g., a buffer such as phosphate buffer which can be administered as pharmaceutical preparations, injection water, or a physiological saline) and dissolving them therein, and then processing the mixture solution into a formulation suitable for parenteral administration such as an intravenous fluid preparation or an injectable solution, and a stabilization method for an albumin preparation.
    Type: Grant
    Filed: February 28, 2003
    Date of Patent: April 1, 2008
    Assignee: Nipro Corporation
    Inventors: Masaki Otagiri, Toshiya Kai, Makoto Sato
  • Publication number: 20080051320
    Abstract: A protein is efficiently nitrosylated with nitrogen monoxide by merely mixing S-nitrosoglutathione as a nitrogen monoxide donor with a protein solution containing a stabilizing agent comprising at least one compound or a combination of plural compounds selected from an N-acetylamino acid, a fatty acid, and a fatty acid salt. The method that enables efficient NO addition to a cysteine residue in un-nitrosylated protein without changing the structure of protein and hence provides NO to a living organism.
    Type: Application
    Filed: August 7, 2007
    Publication date: February 28, 2008
    Inventors: Yu Ishima, Takaaki Akaike, Masaki Otagiri
  • Patent number: 7253259
    Abstract: A protein produced by gene recombinant technology, including at least one domain selected from domains I, II, and III of serum albumin but having a different structure from that of native albumin; and a method of producing the protein. The protein has an enhanced functional activity or activities selected from among various functional activities or serum albumin including antibacterial activity, antioxidative effect, inflammation inhibitory effect, in vivo substance transporting action, and enzymatic activity.
    Type: Grant
    Filed: January 28, 2005
    Date of Patent: August 7, 2007
    Assignee: Nipro Corporation
    Inventors: Masaki Otagiri, Yoshinori Kida, Naohisa Katayama, Toshiya Kai
  • Patent number: 7166577
    Abstract: The present invention provides a nitrosylated albumin variant wherein one or more amino acid residues of constituent amino acid sequences are substituted, or a different amino acid residue is inserted into a part of the constituent amino acid sequences. The albumin variant has sufficient antimicrobial property and permits application as various useful pharmaceutical compositions.
    Type: Grant
    Filed: October 29, 2004
    Date of Patent: January 23, 2007
    Assignee: Nipro Corporation
    Inventors: Masaki Otagiri, Takaaki Akaike
  • Publication number: 20050256303
    Abstract: A protein produced by gene recombinant technology, including at least one domain selected from domains I, II, and III of serum albumin but having a different structure from that of native albumin; and a method of producing the protein. The protein has an enhanced functional activity or activities selected from among various functional activities or serum albumin including antibacterial activity, antioxidative effect, inflammation inhibitory effect, in vivo substance transporting action, and enzymatic activity.
    Type: Application
    Filed: January 28, 2005
    Publication date: November 17, 2005
    Inventors: Masaki Otagiri, Yoshinori Kida, Naoshisa Katayama, Toshiya Kai
  • Publication number: 20050222024
    Abstract: This invention provides albumin preparations with safety and without any risk of side effects, which are free from viruses or contaminating proteins and can be stably stored over a long time while showing neither changes in appearance nor decrease in content. There are provided a stabilized albumin preparation produced by uniformly mixing a medium-chain fatty acid or a salt thereof and a sulfur-containing amino acid or a derivative thereof with an aqueous albumin solution (e.g., a buffer such as phosphate buffer which can be administered as pharmaceutical preparations, injection water, or a physiological saline) and dissolving them therein, and then processing the mixture solution into a formulation suitable for parenteral administration such as an intravenous fluid preparation or an injectable solution, and a stabilization method for an albumin preparation.
    Type: Application
    Filed: February 28, 2003
    Publication date: October 6, 2005
    Inventors: Masaki Otagiri, Toshiya Kai, Makoto Sato
  • Publication number: 20050222026
    Abstract: The present invention provides a nitrosylated albumin variant wherein one or more amino acid residues of constituent amino acid sequences are substituted, or a different amino acid residue is inserted into a part of the constituent amino acid sequences. The albumin variant has sufficient antimicrobial property and permits application as various useful pharmaceutical compositions.
    Type: Application
    Filed: October 29, 2004
    Publication date: October 6, 2005
    Applicant: NIPRO CORPORATION
    Inventors: Masaki Otagiri, Takaaki Akaike